Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board

NHS

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website on a monthly basis

March 2019

 

Pathways and Guidelines Development Subgroup (PaGDSG)

14.3.19

On behalf of the GMMMG Pathways and Guidelines Development Subgroup,  Greater Manchester-wide Guidance for Pain & Symptom Control in Palliative Care is in development.  We now seek comments on this draft. This consultation period is open until 5pm 25th April 2019.

Formulary and Managed Entry Subgroup (FMESG)

18.3.19

Following GM-wide consultation and support from CSB, actions from the November meeting of FMESG have been published. Changes include:

  • DNP listings for cannabis-based, cannabis-derived and hemp products, with the exception of nabilone and Epidiolex. Both of these drugs have been added to the GREY list, with RED RAG status.
  • Imiquimod cream for treatment of superficial basal cell carcinoma was added to formulary as a GREEN (specialist initiation) drug.
  • Uvistat SPF50 has been removed from formulary and replaced with Anthelios XL SPF.
  • Formulary has been updated to reflect that biosimilars are the first choice option for insulin glargine and adalimumab.

The formulary and RAG list have been updated to reflect these changes.

5.3.19

The following actions were proposed at the February 2019  FMESG meeting and will be sent to CSB for pre-support. We now seek comments on these proposals.  This consultation period is open until 5pm on Tuesday 16th April.

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer